Quality of Life in Patients With Bladder Cancer

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying quality of life in patients with bladder cancer may help determine the long-term effects of bladder cancer and may help improve the quality of life for patients in the future. PURPOSE: This clinical trial is studying quality of life in patients with bladder cancer.

Detailed Description
-----------------
OBJECTIVES: To study the effects of recurrence and progression on health-related quality of life (HRQL). To study the effects of repeat cystoscopy on HRQL. To study the patients' assessments of a hypothetical prognostic model and how this affects their preference for the mode of surveillance. OUTLINE: This is a multicenter study. Quality-of-life questionnaires developed by the European Organization for Research and Treatment for Cancer (EORTC) will be used. The EORTC QLQ-BLS24 with 24 questions specific to non-muscle-invasive bladder cancer and the EORTC QLQ-BLM30 with 30 questions specific to muscle-invasive bladder cancer will be combined and used in conjunction with the general cancer questionnaire QLQ-C30. Assessments using the QLQ-C30 will be made at baseline in the entire cohort of patients. Follow-up assessments using the QLQ-C30, QLQ-BLS24, and QLQ-BLM30 167 will be made at first routine follow-up and annually until the end of study. Peer Reviewed and Funded or Endorsed by Cancer Research UK.

Official Title
-----------------
Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [QOL]

Conditions
-----------------
Bladder Cancer

Intervention / Treatment
-----------------
* Procedure: quality-of-life assessment
* Procedure: questionnaire administration


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Inclusion criteria: Enrolled on parent protocol CRUK-BCPP-2005-01 Bladder lesion with cystoscopic characteristics compatible with urothelial cancer or transitional cell carcinoma meeting 1 of the following criteria: Non-muscle-invasive tumor Muscle-invasive tumor Solitary G1 pTa tumor Exclusion criteria: Previous diagnosis of cancer of the urethra, bladder, ureter, or renal pelvis within the 10 years prior to current diagnosis PATIENT CHARACTERISTICS: Inclusion criteria: Fit for cystoscopy and surgical biopsy/resection Exclusion criteria: HIV infection Any condition that, in the opinion of the local investigator, might interfere with the safety of the patient or evaluation of the study objectives PRIOR CONCURRENT THERAPY: Not specified

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: quality-of-life assessment|nan|
|Procedure: questionnaire administration|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life as measured by EORTC QLQ-C30, QLQ-BLS24, and QLQ-BLM30 questionnaires |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
transitional cell carcinoma of the bladder, stage 0 bladder cancer, stage I bladder cancer, stage II bladder cancer